Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q3 2023 · 10-Q
Revenue$15.05M$15.05M+34.9% vs Q3 2022 Net Income-$10.96M-$10.96MN/M vs Q3 2022 EPS Diluted-$0.45-$0.45N/M vs Q3 2022 Gross Profit$10,389,000+41.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,968,000N/M Free Cash Flowderived-$7,102,000N/M Margins · derivedGross margin69.0%+3.4 pt vs Q3 2022
Operating margin-67.6%+17.4 pt vs Q3 2022
Net margin-72.8%+23.2 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end